M.D. Anderson Cancer Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).

2,692 total trials 549 currently recruiting 1201 completed early-phase tilt top decile by trial count

M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.

M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.

Top-decile sponsor footprint

M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

2,692 total, page 27 of 54

TERMINATED Phase 2

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

NCT03360721
COMPLETED Phase 2

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

NCT03370718
TERMINATED Phase 1

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

NCT03101748
COMPLETED NA

REVOLVE or PureGraft Technique in Processing Fat Grafts for Patients Undergoing Breast Reconstruction

NCT03502512
COMPLETED Early Phase 1

Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma

NCT03395847
COMPLETED Phase 2

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT03210662
COMPLETED Early Phase 1

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

NCT03426969
COMPLETED Phase 2

Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast

NCT03063619
TERMINATED Phase 2

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

NCT03404193
COMPLETED Early Phase 1

Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis

NCT03407001
COMPLETED Phase 2

Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy

NCT03319745
COMPLETED NA

Rapid On Site Evaluation of Pleural Touch Preparations in Diagnosing Malignant Pleural Effusion in Patients Undergoing Pleuroscopy

NCT03868579
COMPLETED Phase 1

Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

NCT03290937
COMPLETED Phase 1

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

NCT03390296
COMPLETED

Acceptability of 3D Printed Breast Models as Surgical Decision Aids for Breast Cancer Treatment

NCT04693364
COMPLETED

A Survey of Parent/Caregiver Practices on the Storage, Use, and Disposal of Opioids in a Comprehensive Cancer Center

NCT03390283
TERMINATED Phase 2

Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy

NCT02949947
TERMINATED Phase 2

Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

NCT03274258
TERMINATED Phase 2

Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia

NCT03094611
COMPLETED NA

Ambu AuraGain and Teleflex LMA Protector Fiberoptic Assessments in Elective Patients

NCT02724956
COMPLETED Phase 3

Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway

NCT03359811
COMPLETED Phase 4

Neuromuscular Blockade on Shoulder Pain of Elderly

NCT03210376
COMPLETED

Questionnaires in Assessing Attitudes About Legalization of Marijuana Use in Participants With Cancer

NCT03360799
COMPLETED Phase 1

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

NCT03047993
COMPLETED Phase 1

IACS-010759 in Advanced Cancers

NCT03291938
TERMINATED Phase 2

Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

NCT03022578
COMPLETED Phase 1

Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

NCT03330028
TERMINATED Phase 2

Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT03067571
COMPLETED NA

Very Low Nicotine Content Cigarettes and E-Cigarettes in Promoting Smoking Cessation in Daily and Intermittent Cigarette Smokers

NCT02964182
COMPLETED Phase 2

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

NCT03096782
COMPLETED Phase 2

Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer

NCT03279250
TERMINATED NA

3D Printed Oral Stents for Patients With Head and Neck Cancer Receiving Radiation Therapy

NCT05126797
COMPLETED Phase 2

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

NCT03019640
COMPLETED Phase 2

Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer

NCT03222076
COMPLETED NA

Effect of Physician Attire on Patients' Preference of Physician

NCT03168763
COMPLETED Phase 4

Investigation of Sugammadex in Outpatient Urological Procedures

NCT03138967
COMPLETED Early Phase 1

Oral Supplementation to Enhance Recovery Pilot Study

NCT03204266
TERMINATED Phase 2

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

NCT02730884
TERMINATED Phase 1

Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia

NCT03126864
COMPLETED NA

Impact of a Systematic Social Work Driven Approach on Medical Power of Attorney Documentation, Knowledge, Attitudes, and Beliefs in Participants With Stage I-IV Gynecological Cancers

NCT03037346
COMPLETED Phase 2

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

NCT03204812
COMPLETED Phase 1

Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

NCT03144778
TERMINATED Phase 1

Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy

NCT03106610
COMPLETED Phase 1

Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

NCT03174197
TERMINATED Phase 2

Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

NCT03121534
COMPLETED Phase 1

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

NCT03056339
COMPLETED Phase 2

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

NCT03158129
COMPLETED Phase 2

Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia

NCT02882282
COMPLETED Early Phase 1

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

NCT03132467
COMPLETED Phase 1

Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer

NCT03177460
← Previous Page 27 of 54 Next →

Phase Distribution

PhaseTrial count
Phase 1 748
Phase 2 971
Phase 3 96
Phase 4 28

Therapeutic Areas

Hematopoietic and Lymphoid Cell Neoplasm 44
Malignant Solid Neoplasm 42
Breast Cancer 41
Acute Myeloid Leukemia 38
Leukemia 37
Myelodysplastic Syndrome 33
Lymphoma 32
Cancer 31
Recurrent Acute Myeloid Leukemia 25
Lung Cancer 23

What is open in the M.D. Anderson Cancer Center pipeline

549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).

Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).

Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Related

Compare saved trials side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.